Behavioral Diabetes Institute
N/A
Dr. Polonsky is President and Co-Founder of the Behavioral Diabetes Institute, the world's first organization wholly dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Medicine at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. A licensed clinical psychologist, certified diabetes care and educational specialist, and highly-cited research scientist (with more than 100 peer-reviewed publications in the field of behavioral diabetes), he received the American Diabetes Association’s 2020 Outstanding Educator in Diabetes Award and the American Diabetes Association’s 2014 Richard R. Rubin Award for distinguished contributions to behavioral medicine and psychology.

Presenter of 3 Presentations

Using technology and behavior change to address the hypo averse patient

Session Type
Parallel Session
Date
Thu, 28.04.2022
Session Time
13:00 - 14:30
Room
Hall 116
Lecture Time
13:40 - 14:00

Abstract

Abstract Body

Individuals with type 1 diabetes and type 2 diabetes often harbor excessive worries and concerns regarding hypoglycemia, which can impair their quality of life as well as their ability to achieve favorable glycemic outcomes. Technological interventions, such as the introduction of RT-CGM or hybrid closed-loop pumps, as well as behavioral interventions, such as BGAT (Blood Glucose Awareness Training), have been shown to reduce hypoglycemic fear and/or enhance hypoglycemic confidence, though the effect sizes are typically modest. This presentation will describe how new clinical interventions that integrate the two approaches, both technological and behavioral, may be even more efficacious, especially in those cases where hypoglycemic fears and worries are overwhelming. Through the description of actual cases, practical tips for addressing excessive hypoglycemic worries will be introduced and suggestions for future research investigations will be presented.

Hide

Why is my tech not giving me the results I want

Session Type
Parallel Session
Date
Fri, 29.04.2022
Session Time
16:40 - 18:00
Room
Hall 114
Lecture Time
17:20 - 17:40

Abstract

Abstract Body

When individuals grow discouraged or disappointed with their personal diabetes devices, such as an insulin pump or RT-CGM, it increases the possibility that they will at some point choose to quit their devices altogether. To address this potentially harmful decision in a proactive manner, we must seek to understand the the individual's underlying reasoning and, when needed, develop clear strategies for intervention. This presentation will review how such factors as unreasonable device expectations (e.g., 100% CGM accuracy), history of hypoglycemic fear, and problematic device-related hassles (e.g., alarm fatigue) can all lead to worry, discouragement and potential discontinuation. In addition, practical strategies for addressing these issues will be discussed.

Hide

Medical and psychological approaches towards enhancing the value of personal CGM in the type 2 population

Session Type
Parallel Session
Date
Sat, 30.04.2022
Session Time
11:00 - 12:30
Room
Hall 112
Lecture Time
11:00 - 11:30

Abstract

Abstract Body

Real-time continuous glucose monitoring (RT-CGM) has become the standard of care for people with type 1 diabetes (T1D) and it is the rare individual who would not benefit greatly from it. With the advent of hybrid closed loop systems, RT-CGM has taken on an even greater level of importance. However, the use of RT-CGM in people with type 2 diabetes (T2D) remains very limited.

Currently, only patients with T2D treated with 3 or more injections a day or insulin pump therapy are able to obtain a CGM that is covered by insurance or Medicare in the United States. However, we believe that every patient with T2D, no matter what their current antidiabetic medication regimen may be, could potentially benefit from RT-CGM. The key will be to provide both HCPs and patients with the necessary guidance, education and support to interpret and respond effectively to RT-CGM data. In this presentation, we will put forward a series of practical strategies designed to promote a more successful introduction to RT-CGM for both HCPs and individuals with type 2 diabetes, and also to enhance ease of use and patient enthusiasm regarding RT-CGM as well as long-term glycemic success.

Hide